Revenue
2017
2018
2020
2021
2022
2023
2024
2025
Inmune Bio, Inc. (INMB)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50,000 | $14,000 | $155,000 | $374,000 | $181,000 | $11,000 | — | $0 | $0 |
| Research & development | $20.7M | $33.2M | $20.3M | $17.1M | $20.5M | $5.9M | $3.3M | $3.4M | $435,362 |
| Operating expenses | $47.4M | $42.6M | $29.9M | $26.3M | $29.3M | $12.2M | $7.8M | $12.4M | $981,480 |
| Operating income | −$47.4M | −$42.6M | −$29.7M | −$26.0M | −$29.2M | −$12.2M | −$7.8M | −$12.4M | −$981,480 |
| Net income | −$45.9M | −$42.1M | −$30.0M | −$27.3M | −$30.3M | −$12.1M | −$7.7M | −$12.4M | −$831,486 |
| Basic EPSper diluted share | -$1.86 | -$2.11 | -$1.67 | -$1.52 | -$1.88 | -$1.01 | -$0.75 | -$1.43 | -$0.13 |
| Diluted EPSper diluted share | -$1.86 | -$2.11 | -$1.67 | -$1.52 | -$1.88 | -$1.01 | -$0.75 | -$1.43 | -$0.13 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 30, 2024Form 4 | Moss David JChief Financial Officer | BuyCommon Stock | 10.0K | $5.29 | $52.9K | 1.29M |
| Sep 12, 2024Form 4 | Tesi Raymond JosephPresident and CEO | BuyCommon Stock | 15.4K | $6.38 | $98.1K | 1.55M |
| Sep 12, 2024Form 4 | Tesi Raymond JosephPresident and CEO | BuyCommon Stock Warrants (right to buy) · derivative | 15.4K | $0.13 | $2.0K | 15.4K |
| Sep 12, 2024Form 4 | Moss David JChief Financial Officer | BuyCommon Stock | 7.7K | $6.38 | $49.1K | 1.28M |
| Sep 12, 2024Form 4 | Moss David JChief Financial Officer | BuyCommon Stock Warrants (right to buy) · derivative | 7.7K | $0.13 | $999.70 | 7.7K |